Prime Medicine
Healthcare & Life Sci
Company overview
Prime Medicine develops gene editing treatments for genetic diseases. Its core technology, called Prime Editing, can rewrite small sections of DNA to fix the genetic cause of a disease. The company's patients are people with rare genetic conditions, reached through doctors and hospitals. Prime Medicine is based in Cambridge, Massachusetts.
Prime Medicine was founded in 2019. It is a public company, traded on Nasdaq under the ticker PRME. In October 2024, its treatment PM359 became the first prime-editing therapy to enter clinical trials. That first-in-clinic step means the company's science has moved from the lab into real testing on patients. Prime Medicine is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Cambridge, United States